BioCentury
ARTICLE | Strategy

Indi-Plan B Takes Shape

Neurocrine hopes indiplon now behind it with new deals with Abbott, Boehringer

June 28, 2010 7:00 AM UTC

Neurocrine Biosciences Inc. hopes a pair of recent deals will be transformational for the company in much the same way its 2002 indiplon partnership with Pfizer Inc. was for the biotech's last incarnation - but with a different end result.

On consecutive days this month, Neurocrine announced deals with Abbott Laboratories and Boehringer Ingelheim GmbH that will bring in a total of $85 million up front, additional research and personnel funding, and up to $725 million in milestones, plus royalties...